With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed job losses at one of its UK sites. It is believed about 200 roles ...

GSK is closing down a facility and is winding down antibiotic manufacturing operations at another factory as Novartis’ Sandoz ...

The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...

In 2021, GSK said the factory was likely to close in 2025 when its contract with Sandoz ceased "in the absence of any other ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

If I did not have it, I would certainly use this dip to buy the stock, given its extreme undervaluation and excellent growth prospects. The post With GSK’s share price down 9%, is it time for me to ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

GSK announced positive Phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against ...

GSK recently reported that its asthma drug Nucala (mepolizumab) met the primary endpoint in a Phase III trial treating ...